Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
Hemogenyx Pharmaceuticals announced changes to its share structure following an Extraordinary General Meeting on December 9, 2024. The company's 1,401,815,988 existing ordinary shares underwent a 1:2 subdivision and reclassification, followed by a 400:1 consolidation, resulting in 3,504,539 New Ordinary Shares in issue. Each existing share was split into one new ordinary share of £0.000025 and one deferred share of £0.009975, with the new shares subsequently consolidated.
The New Ordinary Shares will be admitted to trading on the London Stock Exchange's Main Market on December 13, 2024, with a new ISIN: GB00BQVXM815. The Deferred Shares will have no voting rights or capital participation and won't be traded on any exchange.
Hemogenyx Pharmaceuticals ha annunciato modifiche alla propria struttura azionaria a seguito di un'Assemblea Generale Straordinaria tenutasi il 9 dicembre 2024. Le 1.401.815.988 azioni ordinarie esistenti della società sono state sottoposte a una suddivisione e riclassificazione 1:2, seguite da una consolidazione 400:1, portando a 3.504.539 Nuove Azioni Ordinarie emesse. Ogni azione esistente è stata divisa in una nuova azione ordinaria del valore di £0,000025 e in un'azione differita del valore di £0,009975, con le nuove azioni successivamente consolidate.
Le Nuove Azioni Ordinarie saranno ammesse alla negoziazione sul Mercato Principale della Borsa di Londra il 13 dicembre 2024, con un nuovo ISIN: GB00BQVXM815. Le Azioni Differite non avranno diritti di voto né partecipazione al capitale e non saranno negoziate su alcun mercato.
Hemogenyx Pharmaceuticals anunció cambios en su estructura accionarial tras una Junta General Extraordinaria celebrada el 9 de diciembre de 2024. Las 1.401.815.988 acciones ordinarias existentes de la compañía se sometieron a una subdivisión y reclasificación de 1:2, seguida de una consolidación de 400:1, resultando en 3.504.539 Nuevas Acciones Ordinarias en emisión. Cada acción existente fue dividida en una nueva acción ordinaria de £0,000025 y una acción diferida de £0,009975, con las nuevas acciones posteriormente consolidadas.
Las Nuevas Acciones Ordinarias serán admitidas a negociación en el Mercado Principal de la Bolsa de Valores de Londres el 13 de diciembre de 2024, con un nuevo ISIN: GB00BQVXM815. Las Acciones Diferidas no tendrán derechos de voto ni participación de capital y no se negociarán en ningún mercado.
Hemogenyx Pharmaceuticals는 2024년 12월 9일에 열린 임시주주총회에서 주식 구조에 대한 변경 사항을 발표했습니다. 회사의 1,401,815,988개의 기존 보통주는 1:2 비율로 분할 및 재분류되었고, 이후 400:1 비율로 통합되어 3,504,539개의 신규 보통주가 발행되었습니다. 각 기존 주식은 £0.000025의 신규 보통주와 £0.009975의 연기주로 분할되었으며, 신규 주식은 이후 통합되었습니다.
신규 보통주는 2024년 12월 13일 런던 증권거래소의 주 거래시장에 상장되며, 새로운 ISIN: GB00BQVXM815가 부여됩니다. 연기주는 투표권이나 자본 참여가 없으며, 어떤 거래소에서도 거래되지 않습니다.
Hemogenyx Pharmaceuticals a annoncé des modifications de sa structure d'actions à la suite d'une Assemblée Générale Extraordinaire tenue le 9 décembre 2024. Les 1.401.815.988 actions ordinaires existantes de la société ont subi une division et une reclassement de 1:2, suivis d'une consolidation de 400:1, ce qui a abouti à 3.504.539 Nouvelles Actions Ordinaires émises. Chaque action existante a été divisée en une nouvelle action ordinaire de £0,000025 et une action différée de £0,009975, les nouvelles actions ayant ensuite été consolidées.
Les Nouvelles Actions Ordinaires seront admises à la négociation sur le marché principal de la Bourse de Londres le 13 décembre 2024, avec un nouvel ISIN : GB00BQVXM815. Les Actions Différées n'auront pas de droits de vote ni de participation au capital et ne seront négociées sur aucune bourse.
Hemogenyx Pharmaceuticals gab Änderungen an ihrer Aktienstruktur bekannt, die nach einer Außerordentlichen Hauptversammlung am 9. Dezember 2024 beschlossen wurden. Die 1.401.815.988 bestehenden Stammaktien des Unternehmens wurden einer 1:2-Spaltung und Neuklassifizierung unterzogen, gefolgt von einer 400:1-Konsolidierung, was zu 3.504.539 neuen Stammaktien führte. Jede bestehende Aktie wurde in eine neue Stammaktie im Wert von £0,000025 und eine aufgeschobene Aktie im Wert von £0,009975 aufgeteilt, wobei die neuen Aktien anschließend konsolidiert wurden.
Die neuen Stammaktien werden am 13. Dezember 2024 an der Hauptbörse der Londoner Börse zum Handel zugelassen, mit einer neuen ISIN: GB00BQVXM815. Die aufgeschobenen Aktien haben weder Stimmrechte noch Kapitalbeteiligung und werden an keiner Börse gehandelt.
- None.
- None.
Admission of New Ordinary Shares and New ISIN
LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of the New Ordinary Shares (as defined below) further to the passing of all resolutions at its Extraordinary General Meeting (the "Meeting") held on 9 December 2024.
At the Meeting, resolutions were passed to approve the subdivision and reclassification of the Company's existing 1,401,815,988 ordinary shares (the "Existing Ordinary Shares") by 1:2 so that each Existing Ordinary Share was subdivided and reclassified into 1 new ordinary share of £0.000025 each (the "New Ordinary Shares") and 1 deferred share of £0.009975 each (the "Deferred Shares"), followed by a consolidation of the New Ordinary Shares by 400:1 so that every 400 New Ordinary Shares were consolidated into 1 New Ordinary Share of £0.01 each (the "Capital Reorganisation"). As a result of the approval of the Capital Reorganisation, the Company has 3,504,539 New Ordinary Shares in issue.
Admission in respect of such New Ordinary Shares to the transition category of the Official List of the FCA and to trading on the Main Market for listed securities of the London Stock Exchange will become effective and dealings in those New Ordinary Shares is expected on 13 December 2024. As a result of the Capital Reorganisation, the ISIN of the New Ordinary Shares will change from GB00BYX3WZ24 to GB00BQVXM815.
The Deferred Shares have no right to vote or participate in the capital of the Company (save as set out in the Company's Articles of Association) and the Company will not issue any certificates or credit CREST accounts in respect of them. The Deferred Shares will not be admitted to trading on any exchange.
The rights of the New Ordinary Shares and the Deferred Shares are set out in the new Articles of Association as adopted by the Company on 9th December 2024.
The above figure of 3,504,539 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
When will Hemogenyx Pharmaceuticals' new ordinary shares begin trading on LSE?
How many new ordinary shares will Hemogenyx Pharmaceuticals have after the capital reorganization?
What is the new ISIN for Hemogenyx Pharmaceuticals' ordinary shares?
